Clinical trials: Invasive Breast Carcinoma
Breast Cancer
Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2
The goal of this clinical research study is to learn if and how well eribulin, given in combination with standard chemotherapy, can treat early-stage breast cancer compared to paclitaxel given in combination with standard…
- Trial name
- NCT01593020
- Testing
- Paclitaxel, Eribulin, 5-Fluorouracil
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Radiation Therapy in Treating Women With Invasive Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Trial name
- NCT00301041
- Testing
- laboratory biomarker analysis, adjuvant therapy, radiation therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Breast Cancer
Breast Cancer Index (BCI) Registry
The purpose of the Breast Cancer Index (BCI) Registry study is to conduct a large scale, population-based prospective registry to evaluate long-term clinical outcome, clinical impact, medication adherence and quality of life in…
- Trial name
- NCT04875351
- Testing
- Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test
- Where
- 105 sites in United States
- Volunteers
- 3,465 people
- Sponsor
- Biotheranostics, Inc.
Carcinoma, Ductal, Breast, Invasive Breast Cancer
Prediction of Upgrade to Invasive Cancer in Patients Diagnosed With Ductal Carcinoma in Situ by Percutaneous Core Needle Biopsy
It is considered that whether or not the accompanying invasive cancer classified through MRI images of breast cancer patients identified as Ductal Carcinoma in situ (DCIS) through preoperative tissue biopsy is significantly…
- Conditions
- Carcinoma, Ductal, Breast, Invasive Breast Cancer, IMAGE
- Trial name
- NCT04498611
- Testing
- contrast-enhanced breast MRI
- Where
- South Korea
- Volunteers
- 113 people
- Sponsor
- Seoul National University Hospital
Invasive Breast Cancer, Triple Negative Breast Cancer
Sacituzumab Govitecan In TNBC
This research study is studying to evaluate sacituzumab govitecan for individuals with localized triple negative breast cancer (TNBC) The names of the study drugs involved in this study is: Sacituzumab govitecan (SG)…
- Conditions
- Invasive Breast Cancer, Triple Negative Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer
- Trial name
- NeoSTAR (NCT04230109)
- Testing
- Sacituzumab Govitecan, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 239 people
- Sponsor
- Massachusetts General Hospital
Stage I Breast Cancer, Stage II Breast Cancer
A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer
This research study is designed to look at the effects of the combination of vorinostat (Suberoylanilide Hydroxamic Acid or Zolinza) and tamoxifen on breast cancer tissue.
- Conditions
- Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Invasive Breast Cancer
- Trial name
- NCT01194427
- Testing
- Vorinostat and Tamoxifen
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Early-stage Invasive Lobular Breast Carcinoma
AI-based Prognostic Factors Identification in Early-stage Invasive Lobular Breast Carcinoma
Invasive lobular breast carcinoma (ILC), the second most common breast cancer type, represents approximately 15% of all breast cancer cases.
- Trial name
- NCT07842055
- Where
- Greece
- Volunteers
- 3,648 people
- Sponsor
- Hellenic Cooperative Oncology Group
Breast Cancer
Evaluation for the Effectiveness and Safety of Cryo-ablation in the Treatment of Early Invasive Breast Cancer
Recently, researchers in America reported a clinical research (Alliance Z1072) which proved that cryo-ablation could be considered as a non-surgical treatment of early-stage breast cancer.
- Trial name
- NCT04334785
- Testing
- cryo-ablation
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Fudan University
Breast Cancer
Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma
This study is a randomized trial of hypofractionation (short-course) radiation therapy versus conventional radiation therapy in women who have undergone mastectomy and immediate breast reconstruction.
- Trial name
- NCT03422003
- Testing
- Radiation Therapy
- Where
- 15 sites in United States
- Volunteers
- 400 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)
This research study is evaluating how well Breast Cancer responds to preoperative treatment with Endocrine treatment in combination with a drug called Palbociclib or Endocrine treatment alone as possible treatments for Hormone…
- Trial name
- NCT02764541
- Testing
- Letrozole, Tamoxifen, Palbociclib
- Where
- 11 sites in United States
- Volunteers
- 195 people
- Sponsor
- Dana-Farber Cancer Institute
Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma
Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative
This phase II trial studies how well pegylated liposomal doxorubicin, bevacizumab, and everolimus work in treating patients with triple-negative breast cancer with tumors predicted insensitive to standard chemotherapy.
- Trial name
- NCT02456857
- Testing
- Bevacizumab, Everolimus, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Breast Cancer
CRYO-TOUCH: Cryoablation of the Primary Breast Tumor in Metastatic Breast Cancer
Metastatic breast cancer remains an incurable disease for most patients. While surgical treatment of the primary breast tumor is commonly performed in localized breast cancer, its role in metastatic breast cancer remains…
- Trial name
- CRYO-TOUCH (NCT07676344)
- Testing
- Cryoablation, Patient-Reported Outcome Assessment
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Hospices Civils de Lyon
Invasive Breast Cancer
Comparison of CNB and Surgical Specimens for ER, PgR, HER2 Status and Ki67 Index in Invasive Breast Cancer.
This is a prospective, single-center, non-randomized, non-controlled study. The estrogen receptor (ER), progesterone receptor (PgR), HER2 status and Ki67 index of CNB specimen are critical biomarkers for making neoadjuvant…
- Trial name
- NCT02773784
- Testing
- immunohistochemistry and/or FISH
- Where
- China
- Volunteers
- 314 people
- Sponsor
- Peking University
HER2-positive Breast Cancer
A Study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer
A large multi- center phase II/III study with 68Ga-ABY-025 PET and biopsies in patients with advanced HER2-positive breast cancer, where the primary endpoint of the study is to find out the correlation between the HER2 expression…
- Trial name
- Affibody-3 (NCT03655353)
- Testing
- ABY-PET
- Where
- Sweden
- Volunteers
- 160 people
- Sponsor
- Henrik Lindman
Invasive Breast Cancer, Estrogen Receptor Positive Breast Cancer
Breast Density Change Predicting Response to Adjuvant Aromatase Inhibitor
Breast density change after short term use of aromatase inhibitor in postmenopausal ER positive breast cancer would predict endocrine responsiveness
- Trial name
- DEAR (NCT01765049)
- Where
- South Korea
- Volunteers
- 260 people
- Sponsor
- Seoul National University Hospital
Invasive Breast Cancer (Stage I-III)
Neoadjuvant Endocrine Therapy Combined With Chemotherapy in ER-positive, HER2-negative Stage I-III Breast Cancer
The goal of this investigator-initiated, open-label, phase II clinical trial is to evaluate the efficacy and safety of neoadjuvant chemotherapy combined with endocrine therapy in patients with hormone receptor-positive, human…
- Trial name
- NCT07801898
- Testing
- NaCET: For chemotherapy, the TEC or EC-T regimen is selected; for endocrine therapy, letrozole is administered; for premenopausal patients, an LHRH agonist-goserelin or leuprolide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- The Second Hospital of Anhui Medical University
Breast Cancer, Node-negative Breast Cancer
Partial Breast Irradiation Without Sentinel Lymph Node Biopsy in Low-Risk Early Breast Cancer
This is a multicenter, randomized, phase III non-inferiority trial in women aged 40 years or older with clinically node-negative (cN0), pathologically pT1 (≤2 cm), grade 1-2, lymphovascular invasion (LVI)-negative invasive breast…
- Conditions
- Breast Cancer, Node-negative Breast Cancer, Early-Stage Invasive Breast Carcinoma
- Trial name
- APROOB (NCT07757958)
- Testing
- Whole Breast Irradiation, Partial Breast Irradiation
- Where
- South Korea
- Volunteers
- 520 people
- Sponsor
- Samsung Medical Center
Locally Advanced Breast Cancer
Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
This is a prospective, randomised, multicenter, no placebo-controlled, open label study for evaluating the efficacy and safety of pyrotinib in women with residual invasive HER2-positive breast cancer after neoadjuvant…
- Trial name
- ATP (NCT04254263)
- Testing
- pyrotinib
- Where
- China
- Volunteers
- 316 people
- Sponsor
- RenJi Hospital
Breast Cancer, Ductal Carcinoma In Situ
HISMAR: Intraoperative Margin Assessment Using the Histolog® Scanner to Reduce Reoperation in Breast-Conserving Surgery
This study evaluates whether systematic intraoperative margin assessment using the Histolog® Scanner - a confocal fluorescence microscopy device - reduces the need for reoperation after breast-conserving surgery (lumpectomy) in…
- Conditions
- Breast Cancer, Ductal Carcinoma In Situ, Invasive Lobular Carcinoma, Breast Neoplasm Female
- Trial name
- HISMAR (NCT07527468)
- Testing
- Histolog® Scanner
- Where
- Switzerland
- Volunteers
- 228 people
- Sponsor
- Hôpital du Valais
Metastatic Invasive Breast Cancer
Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.
Rationale: In patients with metastatic breast cancer, fragments of tumor DNA called "circulating tumor DNA" or "ctDNA" can be detected in the blood.
- Trial name
- TAILORswitch (NCT07717450)
- Testing
- Tumor assessment, Completion of Quality-of-life questionnaires, ECG
- Volunteers
- 370 people
- Sponsor
- UNICANCER